Objective To investigate the effect of Xuezhokang treatment on blood pressure and pulse pressure(PP) of elderly patients with primary hypertension(PH). Methods Fifty-eight elderly PH patients were treated with Amlodipine(5 mg/d).After the blood pressure were decreased to mild hypertension level,all the patients were randomly divided into 2 groups:30 patients in the Xuezhikang group,and 28 patients in the control group.The patients in the control group were treated with low fat and low salt diet and Amlodipine as before,and the patients in Xuezhikang group were treated not only with Xuezhikang 300 mg twice a day and Amlodipine as before for 12 weeks.Results The SBP and PP(mm Hg)were improved in both Xuezhikang and control groups,and Xuezhikang showed a better therapeutic effect(P＜0.05)than did the control.Xuezhikang group had SBP of(149±9,pretreatment)and(130±8,posttreatment),and PP of(64±11,pretreatment)and (48±7,posttreatment)(all P＜0.05).Control group showed SBP of(144±9)and(130±8)in pre-and post-treatment respectively,and showed PP of(60±10,pre-Rx)and(48±7,post-Rx)(all P＜0.05). Conclusions Anti-hypertensive medications in a routine dose combined with Xuezhikang have a better effect on the hypertension treatment in elderly patients.

Objective To investigate the prognostic value of prognostic nutritional index (PNI) in patients with non-small cell lung cancer.Methods A total of 179 patients with non small cell lung cancer was enrolled in our hospital from November 2010 to January 2014.All patients were pathologically confirmed to be non small cell lung cancer.The clinical data of patients were collected,and the PNI values of each patient were calculated.The patients were divided into 4 groups according to the patients in the PNI of the patients in the treatment group (PNIQ0-25 group,PNIQ25-50 group,PNIQ50-75 group and PNIQ75-100 group).The survival curve was drawn by Kaplan-Meier method,and the difference of progression free survival (DFS) and overall survival (OS) of each group was compared by Log-rank method.Results (1) compared with PNIQ0-25 group,PNIQ25-50 group,PNIQ50-75 group and PNIQ75-100 group,there was signifi cant difference in age,smoking and KPS score (P ＜ 0.05).(2) the PNIQ0-25 group had a median overall survival of 11.5 months (95％ CI:6.6 ～ 15.4),the 3 year survival rate was 6.7％;PNIQ25-50 group had a median overall survival of 12.2 months (95％ CI:9.1 ～ 18),the 3 year survival rate was 6.4％ in PNIQ50-75 group;the median overall survival was 14.1 the month of (95％ CI:8.7 ～ 13.3),the 3 year survival rate was 11.4％,the PNIQ75-100 group had a median overall survival of 15 months (95％ CI:12.3 ～ 17.8),the 3 year survival rate was 11.6％.The Log-rank test,the four groups of patients with a significant difference in overall survival (x2 =15.6,P =0.001).(3) the PNIQ0-25 group had a median progres sion free survival was 5 months for (95％ CI:4.3 ～5.6),the 3 year progression free survival rate was 4.4％;PNIQ25-50 group had a median progression free survival was 6.4 months for (95％ CI:4.7 ～8.1),the 3 year progression free survival rate was 4.3％ in the PNIQ50-75 group;the median progression free survival was 7.4 months (95％ CI:6 ～ 8.7),the 3 year progression free survival rate was 9.1％ in PNIQ75-100 group,the median progression free survival was 8.9 months for (95％ CI:6.4 ～ 10.8),the 3 year progression free survival rate was 9.3％ by Log-rank test,survival was statistically significant was no difference between the four groups (x2 =26.7,P =0.000).Conclusions PNI has a good application value in the prognosis of patients with non-small cell lung cancer.